-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Acepodia is a biotechnology company dedicated to the development of cancerimmunotherapy, ace1702 is a natural killer cell (NK cell) therapy, is being developed to treat HER2-positive solid tumorsPreclinical data for ACE1702 are presented in 2020 at the American Association for Cancer Research (AACR)ACE1702 is an Acepodia cell therapy candidate, and the U.SFood and DrugadministrationAdministration (
FDA) recently approved ace1702's research new drug application (IND) and will be evaluated in Phase I clinical trialsDr Sonny Hsiao, CEO of Acepodia, said: "Solid tumors pose a serious challenge to current cell therapyACE1702 is our first clinical candidate using antibody-cell binding technology that combines the target specificity of antibodies with the anti-tumor capabilities of natural killer cells."in preclinical models, ACE1702 exhibited cytotoxicity to a variety of her2-positive cancer cell lines;